Drug Profile
ALT 005
Alternative Names: ALT005; OpthadineLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Altacor
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ophthalmic infections
Most Recent Events
- 18 Dec 2019 No development reported - Phase-III for Ophthalmic infections (Prevention, In volunteers) in USA (Topical)
- 04 Aug 2015 Altacor has been acquired by Esperante Ventures
- 03 Aug 2015 Clinical development is ongoing for Ophthalmic infections (Prevention)